Clinical Trials Browser

Interventional × VGX-3100 × Clear all

Squamous Intraepithelial Lesions, HIV Seropositivity

NCT03721978 2024-10-17

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Phase 3 Completed

203 enrolled 34 charts

Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Phase 2 Terminated

41 enrolled 13 charts

GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03180684 2023-08-25

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Phase 2 Completed

33 enrolled 19 charts

Gynecologic

Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

NCT03185013 2023-07-27

REVEAL 1

Phase 3 Completed

201 enrolled 23 charts

Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT03499795 2023-07-14

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Phase 2 Completed

23 enrolled 19 charts

GastrointestinalGynecologic

Squamous Intraepithelial Lesions, Anus Neoplasms

NCT02172911 2021-02-21

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Phase 1/2 Completed

10 enrolled 19 charts

Gynecologic

Uterine Cervical Neoplasms

NCT02163057 2021-01-22

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Phase 1/2 Completed

22 enrolled 14 charts

Head & Neck

Head and Neck Squamous Cell Cancer

NCT01188850 2018-08-10

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Phase 1 Completed

14 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00685412 2017-09-13

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Phase 1 Completed

18 enrolled

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Clinical Trials

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

REVEAL 1

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3